The new data – in rare kidney disease IgA nephropathy (IgAN) – comes from the APPLAUSE-IgAN study, with iptacopan achieving a "clinically meaningful and highly statistically significant ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

IgA nephropathy drugs that work via other mechanisms include delayed-release budesonide (Tarpeyo), sparsentan (Filspari), and iptacopan (Fabhalta). "Today's approval marks an important milestone ...

Multiple medications are now available to treat IgA nephropathy, including budesonide (Tarpeyo), sparsentan (Filspari), and iptacopan (Fabhalta). But Miller’s treatment options were more limited ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat patients with the rare kidney disease immunoglobulin A nephropathy ...

Iptacopan is also approved for paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy, with ongoing studies in other kidney conditions. Iptacopan's (Fabhalta; Novartis ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

Immunoglobulin A (IgA) nephropathy is a condition that causes a certain type of protein to build up in your kidneys. It progresses differently in everyone. Your kidneys might still work well years ...

IgA nephropathy is the leading cause of kidney failure. Around half of those with IgA nephropathy will see worsening kidney function over many years. For some people, this happens more quickly.